Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel nanocatalytic compounds designed to address degenerative and neurodegenerative disorders. Headquartered in Salt Lake City, Utah, Clene leverages proprietary gold nanocrystal technology to create therapies that enhance cellular bioenergetics and mitigate oxidative stress—mechanisms believed to play critical roles in slowing or reversing disease progression.
The company’s lead investigational product, CNM-Au8®, is an orally administered, clean-surfaced gold nanocrystal suspension engineered to catalytically support neuron health. CNM-Au8 has been studied across multiple clinical programs targeting amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. Clene’s research suggests that its nanocatalysts may bolster cellular energy production, promote remyelination, and reduce harmful reactive oxygen species, offering a novel approach compared with conventional small-molecule or biologic therapies.
Clene’s pipeline extends beyond its lead asset, with preclinical efforts exploring additional indications linked to oxidative stress and mitochondrial dysfunction. The company has completed Phase 2 trials in Parkinson’s disease and ALS, and it continues to advance these programs through regulatory interactions and investigator-sponsored studies. By collaborating with academic institutions and leading neurology centers across North America, Clene aims to generate robust clinical evidence for its unique mechanism of action.
Since its inception, Clene has pursued both U.S. and Canadian clinical development pathways and maintains corporate offices and research facilities in Salt Lake City. The company’s management team brings experience from the biotechnology and pharmaceutical industries, with a focus on translating cutting-edge nanotechnology into therapeutic candidates. Clene is publicly traded on the Nasdaq under the ticker symbol CLNNW.
AI Generated. May Contain Errors.
Free CLNNW Stock Alerts